Results 81 to 90 of about 11,239 (184)

Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study

Journal of Arrhythmia, 2019
Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial fibrillation (NVAF).
Hiroshi Inoue, Michiaki Umeyama, Takako Yamada, Hiroyuki Hashimoto, Akira Komoto, Masahiro Yasaka   +5 more
doaj   +1 more source

Characteristics of “Hard-to-Use” Press-Through-Package Sheets: An Analysis of Information Collected by Marketing Specialists of a Japanese Medical Wholesaler

Patient Preference and Adherence, 2020
Kenji Kabeya,1 Hiroki Satoh,2,3 Satoko Hori,4 Yasumasa Miura,5 Yasufumi Sawada2 1Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan; 2Laboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The ...
Kabeya K, Satoh H, Hori S, Miura Y, Sawada Y   +4 more
doaj  

Postmarket Surveillance of Neuroendovascular Devices

Stroke: Vascular and Interventional Neurology
Endovascular devices have catalyzed a global industry for advanced technologies such as flow diverters and stent retrievers. Though adoption of these devices has skyrocketed over the past 30 years, the regulatory landscape for real‐world monitoring is constantly under revision.
Marie K. Luff, Art Sedrakyan, Sameer A. Ansari, Adnan H. Siddiqui, David S. Liebeskind   +4 more
openaire   +3 more sources

In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorthiazide, among Palestinian hypertensive patients

Therapeutics and Clinical Risk Management, 2016
Abdel Naser Zaid,1 Masshour Ghanem,2 Dua’a Shweiki,1 Hala Shtewi,1 Raja’ Shaheen,1 Sondos Al Helaly,1 Zeina Khayyat,1 Rowa’a Al Ramahi,1 Sa’ed H Zyoud1 1Department of Pharmacy, Faculty of Medicine & Health Sciences, An-Najah ...
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH   +8 more
doaj  

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

Drug, Healthcare and Patient Safety, 2015
Michele Jara, Thomas Aquilina, Peter Aupperle, Adrian L Rabinowicz Acorda Therapeutics, Inc., Ardsley, NY, USA Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US ...
Jara M, Aquilina T, Aupperle P, Rabinowicz AL   +3 more
doaj  

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

BMC Gastroenterology
Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological
Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao   +7 more
doaj   +1 more source

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events

Clinical and Translational Science, 2022
John T. Sullivan
doaj   +1 more source

Postmarketing Commitment [PDF]

, 2020
openaire   +1 more source

Association of Guillain-Barré Syndrome With Nonavalent Human Papillomavirus Vaccine: A Postmarketing Drug Safety Study. [PDF]

Obstet Gynecol Int
González Mariño MA.
europepmc   +1 more source

Postmarketing Surveillance [PDF]

, 2020
openaire   +1 more source